Narendranath Epperla
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (NCT04836832) | Narendranath Epperla | 2022-07-01 |
Track Narendranath Epperla automatically
Every clearance here is in the API, with alerts when new ones post.